Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia.

Thomas X, Paubelle E.

Expert Opin Biol Ther. 2018 Nov;18(11):1095-1106. doi: 10.1080/14712598.2018.1533951. Epub 2018 Oct 12. Review.

PMID:
30296188
2.

Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia.

Liu Y, Chen X, Han W, Zhang Y.

Drugs Today (Barc). 2017 Nov;53(11):597-608. doi: 10.1358/dot.2017.53.11.2725754. Review.

PMID:
29451276
3.

CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.

Pehlivan KC, Duncan BB, Lee DW.

Curr Hematol Malig Rep. 2018 Oct;13(5):396-406. doi: 10.1007/s11899-018-0470-x. Review.

PMID:
30120708
4.

CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia.

Vairy S, Garcia JL, Teira P, Bittencourt H.

Drug Des Devel Ther. 2018 Nov 12;12:3885-3898. doi: 10.2147/DDDT.S138765. eCollection 2018. Review.

5.

Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia.

Leahy AB, Elgarten CW, Grupp SA, Maude SL, Teachey DT.

Expert Rev Anticancer Ther. 2018 Oct;18(10):959-971. doi: 10.1080/14737140.2018.1512411. Review.

PMID:
30111196
6.

Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.

Cai B, Guo M, Wang Y, Zhang Y, Yang J, Guo Y, Dai H, Yu C, Sun Q, Qiao J, Hu K, Zuo H, Dong Z, Zhang Z, Feng M, Li B, Sun Y, Liu T, Liu Z, Wang Y, Huang Y, Yao B, Han W, Ai H.

J Hematol Oncol. 2016 Nov 25;9(1):131.

7.

CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.

Singh N, Frey NV, Grupp SA, Maude SL.

Curr Treat Options Oncol. 2016 Jun;17(6):28. doi: 10.1007/s11864-016-0406-4. Review.

PMID:
27098534
8.

CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies.

Turtle CJ, Riddell SR, Maloney DG.

Clin Pharmacol Ther. 2016 Sep;100(3):252-8. doi: 10.1002/cpt.392. Epub 2016 Jun 17.

PMID:
27170467
9.

At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies.

Oluwole OO, Davila ML.

J Leukoc Biol. 2016 Dec;100(6):1265-1272. Epub 2016 Jun 27. Review.

PMID:
27354412
10.

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.

Maude SL, Teachey DT, Porter DL, Grupp SA.

Blood. 2015 Jun 25;125(26):4017-23. doi: 10.1182/blood-2014-12-580068. Epub 2015 May 21. Review.

11.

CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia.

Lorentzen CL, Straten PT.

Scand J Immunol. 2015 Oct;82(4):307-19. doi: 10.1111/sji.12331. Review.

12.

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL.

Lancet. 2015 Feb 7;385(9967):517-528. doi: 10.1016/S0140-6736(14)61403-3. Epub 2014 Oct 13.

PMID:
25319501
13.

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.

Kochenderfer JN, Rosenberg SA.

Nat Rev Clin Oncol. 2013 May;10(5):267-76. doi: 10.1038/nrclinonc.2013.46. Epub 2013 Apr 2. Review.

14.

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA.

N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866.

15.
16.

Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation.

Schubert ML, Hückelhoven A, Hoffmann JM, Schmitt A, Wuchter P, Sellner L, Hofmann S, Ho AD, Dreger P, Schmitt M.

Hum Gene Ther. 2016 Oct;27(10):758-771. doi: 10.1089/hum.2016.097. Epub 2016 Jul 31.

PMID:
27479233
17.

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA.

J Clin Oncol. 2015 Feb 20;33(6):540-9. doi: 10.1200/JCO.2014.56.2025. Epub 2014 Aug 25.

18.

Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.

Zhang T, Cao L, Xie J, Shi N, Zhang Z, Luo Z, Yue D, Zhang Z, Wang L, Han W, Xu Z, Chen H, Zhang Y.

Oncotarget. 2015 Oct 20;6(32):33961-71. doi: 10.18632/oncotarget.5582.

19.

CD19 CAR Therapy for Acute Lymphoblastic Leukemia.

Sadelain M, Brentjens R, Rivière I, Park J.

Am Soc Clin Oncol Educ Book. 2015:e360-3. doi: 10.14694/EdBook_AM.2015.35.e360. Review.

20.

[Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].

Li HH, Zhu P, Wu XQ, Liu YF.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Dec;22(6):1753-6. doi: 10.7534/j.issn.1009-2137.2014.06.047. Review. Chinese.

PMID:
25543510

Supplemental Content

Support Center